Community-driven development of a modified progression-free survival ratio for precision oncology

OBJECTIVE: Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecularly guided therapy (PFS2) divided by the PFS int...

Descripción completa

Detalles Bibliográficos
Autores principales: Mock, Andreas, Heilig, Christoph E, Kreutzfeldt, Simon, Huebschmann, Daniel, Heining, Christoph, Schröck, Evelin, Brors, Benedikt, Stenzinger, Albrecht, Jäger, Dirk, Schlenk, Richard, Glimm, Hanno, Fröhling, Stefan, Horak, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863673/
https://www.ncbi.nlm.nih.gov/pubmed/31798980
http://dx.doi.org/10.1136/esmoopen-2019-000583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863673/
https://www.ncbi.nlm.nih.gov/pubmed/31798980
http://dx.doi.org/10.1136/esmoopen-2019-000583

Ejemplares similares